With its rapidly produced and highly effective coronavirus vaccine, it's no surprise that Moderna (NASDAQ: MRNA) is one of the most-discussed stocks of the year. Right now, Moderna's market capitalization is about $137 billion. Moderna's trailing revenue is $2.73 billion, but it already has signed advance purchase agreements that should total $19.2 billion before the end of 2021.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting